Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 36.22
SGNT's Cash to Debt is ranked higher than
64% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. SGNT: 36.22 )
Ranked among companies with meaningful Cash to Debt only.
SGNT' s 10-Year Cash to Debt Range
Min: 0.96  Med: 36.22 Max: No Debt
Current: 36.22
Equity to Asset 0.73
SGNT's Equity to Asset is ranked higher than
66% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SGNT: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
SGNT' s 10-Year Equity to Asset Range
Min: -1.15  Med: 0.73 Max: 0.82
Current: 0.73
-1.15
0.82
Interest Coverage 6.64
SGNT's Interest Coverage is ranked lower than
84% of the 389 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. SGNT: 6.64 )
Ranked among companies with meaningful Interest Coverage only.
SGNT' s 10-Year Interest Coverage Range
Min: 6.64  Med: 33.74 Max: 9999.99
Current: 6.64
6.64
9999.99
F-Score: 4
Z-Score: 4.76
M-Score: 0.25
WACC vs ROIC
10.79%
31.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 3.27
SGNT's Operating margin (%) is ranked lower than
63% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. SGNT: 3.27 )
Ranked among companies with meaningful Operating margin (%) only.
SGNT' s 10-Year Operating margin (%) Range
Min: -258.05  Med: -14.22 Max: 12.82
Current: 3.27
-258.05
12.82
Net-margin (%) 9.56
SGNT's Net-margin (%) is ranked higher than
62% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. SGNT: 9.56 )
Ranked among companies with meaningful Net-margin (%) only.
SGNT' s 10-Year Net-margin (%) Range
Min: -253.66  Med: -17.34 Max: 13.8
Current: 9.56
-253.66
13.8
ROE (%) 11.20
SGNT's ROE (%) is ranked higher than
63% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. SGNT: 11.20 )
Ranked among companies with meaningful ROE (%) only.
SGNT' s 10-Year ROE (%) Range
Min: -26.08  Med: 1.65 Max: 16.09
Current: 11.2
-26.08
16.09
ROA (%) 8.35
SGNT's ROA (%) is ranked higher than
70% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. SGNT: 8.35 )
Ranked among companies with meaningful ROA (%) only.
SGNT' s 10-Year ROA (%) Range
Min: -52.59  Med: -11.75 Max: 12.27
Current: 8.35
-52.59
12.27
ROC (Joel Greenblatt) (%) 7.86
SGNT's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. SGNT: 7.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGNT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -441.12  Med: -72.29 Max: 49.31
Current: 7.86
-441.12
49.31
Revenue Growth (3Y)(%) 5.20
SGNT's Revenue Growth (3Y)(%) is ranked lower than
52% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. SGNT: 5.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGNT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -17.40 Max: 46.4
Current: 5.2
0
46.4
» SGNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SGNT Guru Trades in Q3 2014

Joel Greenblatt 6,822 sh (New)
Paul Tudor Jones 12,700 sh (-30.22%)
NWQ Managers 517,326 sh (-35.50%)
» More
Q4 2014

SGNT Guru Trades in Q4 2014

Jim Simons 17,000 sh (New)
Joel Greenblatt 19,886 sh (+191.50%)
Paul Tudor Jones 26,900 sh (+111.81%)
NWQ Managers 525,491 sh (+1.58%)
» More
Q1 2015

SGNT Guru Trades in Q1 2015

George Soros 115,500 sh (New)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones 11,900 sh (-55.76%)
NWQ Managers 72,373 sh (-86.23%)
» More
Q2 2015

SGNT Guru Trades in Q2 2015

Steven Cohen 244,900 sh (New)
Jim Simons 90,700 sh (New)
George Soros 347,200 sh (+200.61%)
Paul Tudor Jones 22,692 sh (+90.69%)
NWQ Managers Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.36
SGNT's P/E(ttm) is ranked higher than
68% of the 479 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. SGNT: 22.36 )
Ranked among companies with meaningful P/E(ttm) only.
SGNT' s 10-Year P/E(ttm) Range
Min: 18.76  Med: 27.35 Max: 473.95
Current: 22.36
18.76
473.95
Forward P/E 18.73
SGNT's Forward P/E is ranked higher than
63% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. SGNT: 18.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.40
SGNT's PE(NRI) is ranked higher than
68% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. SGNT: 22.40 )
Ranked among companies with meaningful PE(NRI) only.
SGNT' s 10-Year PE(NRI) Range
Min: 18.74  Med: 27.33 Max: 473.95
Current: 22.4
18.74
473.95
P/B 2.40
SGNT's P/B is ranked higher than
60% of the 644 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. SGNT: 2.40 )
Ranked among companies with meaningful P/B only.
SGNT' s 10-Year P/B Range
Min: 2.27  Med: 3.39 Max: 5.06
Current: 2.4
2.27
5.06
P/S 2.11
SGNT's P/S is ranked higher than
63% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.13 vs. SGNT: 2.11 )
Ranked among companies with meaningful P/S only.
SGNT' s 10-Year P/S Range
Min: 0.46  Med: 2.58 Max: 3.94
Current: 2.11
0.46
3.94
POCF 402.26
SGNT's POCF is ranked lower than
99% of the 387 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.20 vs. SGNT: 402.26 )
Ranked among companies with meaningful POCF only.
SGNT' s 10-Year POCF Range
Min: 11.47  Med: 24.04 Max: 518.4
Current: 402.26
11.47
518.4
EV-to-EBIT 74.41
SGNT's EV-to-EBIT is ranked lower than
84% of the 488 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.19 vs. SGNT: 74.41 )
Ranked among companies with meaningful EV-to-EBIT only.
SGNT' s 10-Year EV-to-EBIT Range
Min: -38.3  Med: 19.50 Max: 331.9
Current: 74.41
-38.3
331.9
Current Ratio 2.39
SGNT's Current Ratio is ranked higher than
51% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. SGNT: 2.39 )
Ranked among companies with meaningful Current Ratio only.
SGNT' s 10-Year Current Ratio Range
Min: 1.57  Med: 3.61 Max: 4.65
Current: 2.39
1.57
4.65
Quick Ratio 1.56
SGNT's Quick Ratio is ranked lower than
52% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. SGNT: 1.56 )
Ranked among companies with meaningful Quick Ratio only.
SGNT' s 10-Year Quick Ratio Range
Min: 0.89  Med: 2.47 Max: 3.74
Current: 1.56
0.89
3.74
Days Inventory 91.20
SGNT's Days Inventory is ranked higher than
61% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.66 vs. SGNT: 91.20 )
Ranked among companies with meaningful Days Inventory only.
SGNT' s 10-Year Days Inventory Range
Min: 97.42  Med: 104.08 Max: 161.55
Current: 91.2
97.42
161.55
Days Sales Outstanding 52.22
SGNT's Days Sales Outstanding is ranked higher than
67% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.39 vs. SGNT: 52.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGNT' s 10-Year Days Sales Outstanding Range
Min: 6.35  Med: 62.83 Max: 93.34
Current: 52.22
6.35
93.34

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.42
SGNT's Price/Net Current Asset Value is ranked higher than
55% of the 385 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. SGNT: 6.42 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGNT' s 10-Year Price/Net Current Asset Value Range
Min: 4.01  Med: 4.89 Max: 8.66
Current: 6.42
4.01
8.66
Price/Tangible Book 3.40
SGNT's Price/Tangible Book is ranked higher than
53% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. SGNT: 3.40 )
Ranked among companies with meaningful Price/Tangible Book only.
SGNT' s 10-Year Price/Tangible Book Range
Min: 2.92  Med: 3.90 Max: 5
Current: 3.4
2.92
5
Price/Projected FCF 5.74
SGNT's Price/Projected FCF is ranked lower than
74% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. SGNT: 5.74 )
Ranked among companies with meaningful Price/Projected FCF only.
SGNT' s 10-Year Price/Projected FCF Range
Min: 6.97  Med: 8.59 Max: 10.2
Current: 5.74
6.97
10.2
Price/Median PS Value 0.82
SGNT's Price/Median PS Value is ranked higher than
81% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. SGNT: 0.82 )
Ranked among companies with meaningful Price/Median PS Value only.
SGNT' s 10-Year Price/Median PS Value Range
Min: 0.23  Med: 0.99 Max: 1.46
Current: 0.82
0.23
1.46
Price/Graham Number 1.83
SGNT's Price/Graham Number is ranked higher than
61% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. SGNT: 1.83 )
Ranked among companies with meaningful Price/Graham Number only.
SGNT' s 10-Year Price/Graham Number Range
Min: 1.8  Med: 2.16 Max: 7.66
Current: 1.83
1.8
7.66
Earnings Yield (Greenblatt) (%) 1.28
SGNT's Earnings Yield (Greenblatt) (%) is ranked lower than
60% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. SGNT: 1.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGNT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 2.50 Max: 6.7
Current: 1.28
0.3
6.7

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 327 414 458
EPS($) 0.19 1.07 1.30
EPS without NRI($) 0.19 1.07 1.30

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S06.Germany,
Sagent Pharmaceuticals Inc is a Delaware corporation that was incorporated in 2011. The Company was initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, it reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation, in connection with its initial public offering, on April 26, 2011. The Company is engaged in the developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which it sells primarily in the United States of America. The Company primarily focuses on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, it offers customers, products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. It generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. At the year end, the Company's product portfolio has grown to a total of 53 products which can be classified into the following three product categories: anti-infective, oncology and critical care. Its anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. The Company distributes its products primarily through pharmaceutical wholesalers and, to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by a wide variety of end-users, including U.S. hospitals, integrated delivery networks and alternative site facilities. The Company's principal competitors include Fresenius Kabi, a division of Fresenius SE, Hospira, Inc., Pfizer Inc., Sandoz International GmbH, a division of Novartis AG, Teva Pharmaceutical Industries Ltd. and West-Ward Pharmaceutical Corp. The Company is subject to extensive regulation by governmental authorities in the U.S. and in other countries.
» More Articles for NAS:SGNT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Put Impax, Akorn and Sagent on Your Watch List of Generics Targets Aug 25 2015
SAGENT PHARMACEUTICALS, INC. Financials Aug 12 2015
10-Q for Sagent Pharmaceuticals, Inc. Aug 06 2015
Edited Transcript of SGNT earnings conference call or presentation 4-Aug-15 1:00pm GMT Aug 04 2015
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2015
Sagent reports 2Q loss Aug 04 2015
Sagent reports 2Q loss Aug 04 2015
Q2 2015 Sagent Pharmaceuticals Inc Earnings Release - Before Market Open Aug 04 2015
Sagent Pharmaceuticals Reports Second Quarter 2015 Financial Results Aug 04 2015
Sagent Pharmaceuticals Board Appoints Allan Oberman as Chief Executive Officer Aug 03 2015
Sagent Pharmaceuticals Sets Date and Time for Release of Second Quarter 2015 Results Jul 28 2015
Medicines Co., Eagle Pharma Up On Analyst Actions Jul 06 2015
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers Jun 11 2015
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 11 2015
Coverage initiated on Sagent Pharma by Raymond James Jun 03 2015
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... May 13 2015
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... May 08 2015
Sagent reports 1Q loss May 05 2015
Sagent reports 1Q loss May 05 2015
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK